Cite
MLA Citation
J Kay et al.. “OP0203 Impact of adalimumab serum concentration on efficacy and association between ANTI-DRUG antibodies and serum concentration: 24 week results from a phase III study comparing SB5 (an adalimumab biosimilar) with reference adalimumab in patients with rheumatoid arthritis.” Annals of the rheumatic diseases, vol. 76, n.d., p. 136. http://access.bl.uk/ark:/81055/vdc_100135160667.0x000059